Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

ALLO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Allogene Therapeutics, Inc.NASDAQ: ALLO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $8.27M fell 32.1% year over year, ahead of the -35.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at -23.4% a year.

Context

  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -32.1% holds above the trailing-twelve-month pace of -35.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.27M+1.7% QoQ
Last fiscal yearDec 2025
$37.64M-27.3% YoY
LTMMar 2026
$33.74M-35.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.1%——
1 year-27.3%——
3-year CAGR-23.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
37.64M USD
Year-over-year change
-27.3%
4-year CAGR
-17.4%

Stock-Based Compensation vs competitors

How ALLO compares with its peers on the latest reported figures

  • ALLO's LTM Mar 2026 stock-based compensation of $33.74M is the largest of the 9 companies compared; the peer median is $9.65M.
  • Its year-over-year change of -35.1% is the 5th highest of 9, against a peer median of -38.1%.
  • Over three fiscal years its annual growth of -23.4% compares with a peer median of -13.8%.
ALLO Competitors Peer median
Stock-Based Compensation for ALLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M -35.1%-23.4%—
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M -43.3%-31.8%340.0%
AUTLAutolus Therapeutics plcLTM Mar 2026$15.14M -5.7%+6.3%16.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
CELUCelularity Inc.LTM Dec 2025$10.38M -11.5%-13.2%39.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$8.91M -28.8%-19.0%19.8%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$6.29M -72.4%-43.4%27.2%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$5.86M -50.8%-13.8%—
CLLSCellectis S.A.LTM Mar 2026$1.28M -60.6%—1.9%
Peer median (excluding ALLO) $9.65M-38.1%-13.8%27.2%

Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(257.01M)(332.63M)(327.27M)(257.59M)(190.89M)
Depreciation & Amortization10.45M14.3M14.2M13.64M12.36M
Deferred Income Tax10.4M8.08M0443K0
Stock-Based Compensation80.82M83.6M65.95M51.74M37.64M
Change in Working Capital(32.09M)3.71M(15.31M)(24.8M)(10.88M)
Accounts Receivables00000
Inventory00000
Accounts Payables(767K)4.87M(7.5M)(503K)(1.23M)
Other Working Capital(31.32M)(1.16M)(7.8M)(24.3M)(9.65M)
Other Non-Cash Items2.61M2.43M24.69M16.26M2.52M
Operating Cash Flow(184.81M)(220.52M)(237.73M)(200.3M)(149.25M)
Capital Expenditures(21.45M)(5.19M)(1.52M)(694K)(386K)
Acquisitions (Net)(17.71M)(111.35M)000
Purchases of Investments(525.58M)(248.11M)(438.63M)(361.48M)(138.26M)
Sales of Investments728.39M359.46M603.43M437.86M234.2M
Other Investing Activities0111.35M000
Investing Cash Flow163.66M106.16M163.29M75.69M95.56M
Debt Repayment00000
Common Stock Issued11.96M2.95M91.11M114.4M23.25M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities004.58M2.28M6.91M
Financing Cash Flow11.96M2.95M95.7M116.68M30.16M
Effect of Forex Changes00000
Net Change in Cash(9.19M)(111.41M)21.25M(7.94M)(23.53M)
Free Cash Flow(206.26M)(225.71M)(239.25M)(200.99M)(149.63M)

Allogene Therapeutics, Inc.

NASDAQ:ALLO

Intrinsic Alpha fair value

Locked

Current Price

$0.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.